University System of Maryland

Johns Hopkins University

Princeton University

Gpb Scientific, LLC

Becton Dickinson and Company Limited

University of Pennsylvania

Zeon Corportion

Curt I Civin

James Christopher Sturm

Robert H Austin

Michael Grisham

Khushroo Gandhi

Alison Skelley

Anthony Ward

Joseph D'Silva

Roberto Campos-Gonzalez

Donald Small

Lee Aurich

Meredith G Safford

Drew M Pardoll

Gary H Posner

Yu Chen

Michael R Loken

Alan M Gewirtz

Virendra O Shah

Joseph D'silva

Linzhao Cheng

Yan Cui

Katherine Whartenby

Blake S Moses

Xiaochun Chen

Jennifer Fox

Michelle Rudek

Robert W Georgantas, Iii

Described herein are microfluidic devices and methods that can separate and concentrate particles in a sample.

Methods and devices for multi-step cell purification and concentration

Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and one or more additional therapeutic agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, ART-631, and ART-838. The one or more additional therapeutic agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.

Combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors for cancer treatment

Described herein are microfluidic devices and methods that can greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas.

On-chip microfluidic processing of particles

Described herein are devices and methods for high throughput purification of particles. In some cases, methods and devices described herein can be used to remove erythrocytes and purify leukocytes and raise the quality of umbilical cord blood and other transplant grafts, thereby significantly improving patient outcomes.

Methods and devices for high throughput purification

The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

Methods for preparing therapeutically active cells using microfluidics

Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of UCB and other transplant grafts, thereby significantly improving patient outcomes.

High efficiency microfluidic purification of stem cells to improve transplants

Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and ART-838. The second agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.

Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents

The invention is based at least in part on the discovery of novel group of genes and/or their encoded gene products that are differentially represented in two substantially enriched CD34/CD38/Linand CD34/[CD38/Lin]hematopoietic cell populations isolated from normal human bone marrow, cord blood, and peripheral blood stem cell preparations.

Therapeutic and diagnostic applications of genes differentially expressed in lympho-hematopoietic stem cells

The invention provides methods and compositions for the modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules. The invention includes bi-cistronic lentiviral expression vectors adapted for antigen expression in antigen presenting cells for use in DNA vaccines directed against pathogens and tumor antigens as well as for the treatment of autoimmune disease and for the establishment of antigen tolerance.

Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules

Growing community of inventors

Baltimore, MD, United States of America

Curt I Civin